Eton Pharmaceuticals Inc
etonpharma.comEton Pharmaceuticals (NASDAQ: ETON) is a specialty pharmaceutical company that acquires, develops, and commercializes treatments for rare and ultra-rare diseases. Revenue comes primarily from direct product sales of FDA-approved drugs, with additional income from licensing arrangements that can include milestone payments and sales-based royalties. The company sells its commercial products through an internal sales force and outsources manufacturing to third-party contract manufacturers. Marketed products as of the FY2025 10-K (filed 2026-03-19) include INCRELEX, ALKINDI SPRINKLE, KHINDIVI, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous for Oral Solution, and Nitisinone, all targeting small patient populations with limited treatment alternatives. Pipeline candidate ET-600 had its NDA accepted by the FDA with a PDUFA date of February 25, 2026, with launch inventory scheduled for Q1 2026. The company carries debt through a credit agreement with SWK Funding LLC, amended most recently in September 2024.
Products & Services
INCRELEX, ALKINDI SPRINKLE, KHINDIVI, GALZIN, PKU GOLIKE (branded products); Carglumic Acid (generic of Carbaglu, launched December 2021); Betaine Anhydrous for Oral Solution (generic of Cystadane, launched May 2023); Nitisinone (generic of Orfadin, launched February 2024); ET-600 (NDA under FDA review, PDUFA date February 25, 2026).
Revenue Model
Product sales of FDA-approved rare-disease drugs sold through an internal sales force; licensing revenue from partners including development milestone payments recognized upon achievement and sales-based royalties recognized when underlying sales occur.
Customers & Markets
Patients with rare and ultra-rare inherited metabolic and endocrine conditions in the United States. End markets include NAGS deficiency, homocystinuria (estimated fewer than 2,000 U.S. patients), tyrosinemia type 1 (estimated fewer than 500 U.S. patients), and related rare pediatric disorders. Eton products are prescribed to very few Medicare patients, per FY2025 10-K disclosure.
Geographic Exposure
United States primary commercial market, based on product approvals and sales force described in FY2025 10-K filing.
Financial Snapshot
Loading...
